Ladies and gentlemen, good day and welcome to Dr. Lal PathLabs Q2 FY 2026 earnings conference call. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on a touch-tone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Nishid Solanki from CDR India. Thank you, and over to you, sir.
Thank you. Good afternoon, everyone, and welcome to Dr. Lal PathLabs Q2 FY 2026 earnings conference call. Today, we are joined by senior members of the management team, including Honorary Brigadier Dr. Arvind Lal, Executive Chairman, Mr. Shankha Banerjee, CEO, and Mr. Ved Prakash Goel, Group CFO and CEO, International Business. I would like to share a standard disclaimer. Some of the statements made on today's conference call could be forward-looking in nature, and the actual results could vary from these forward-looking statements. A detailed disclaimer in this regard is available in the results presentation, which has been circulated to you and also available on stock exchange websites. I would now like to invite Dr. Arvind Lal to share his perspectives. Thank you, and over to you, sir.
Thank you, Nishid. Good evening, ladies and gentlemen. Thank you for taking out the time and joining us on our second quarter and half-yearly earnings call for fiscal 2026. Healthcare in India stands at a crucial inflection point. The sector continues to expand at a healthy pace, shaped by both demographic realities and transformative policy shifts. Initiatives like Ayushman Bharat are steadily broadening access, with millions of new admissions under coverage and hospitals being empanelled at a fast pace. This is opening the doors of organized healthcare to Tier 2 and Tier 3 cities in India, creating a structured tailwind for quality diagnostic services also. As India accelerates Healthcare Spend, it is imperative that early detection and diagnostics must be at the heart of this National Healthcare Agenda. Another trend that is gaining momentum is the Rapid Digitization of the Healthcare D elivery.
The Ayushman Bharat Digital Mission and other incentive schemes are pushing adoption of standardized digital workflows across hospitals and labs. This shift is not merely administrative, it is also redefining the patient's experience, ensuring better traceability, enabling us to integrate our services more efficiently. For diagnostic players with established digital infrastructure like ours, this is a significant advantage. Turning to disease patterns, Non-Dommunicable diseases remain the most pressing Healthcare challenge for the country. Cardiometabolic demands stay elevated, and India continues to grapple with high burdens of diabetes, hypertension, and obesity, conditions that increasingly require continuous monitoring and preventive testing. At the same time, environmental factors like air quality and lifestyle shifts are compounding risks, expanding the population that requires regular testing and early interventions. These developments translate directly into higher demand for chronic care diagnostics, preventive panels, and high-end testing across the country. The diagnostic sector is undergoing gradual consolidation.
Organized chains still account for less than 1/5 of the overall market. However, the bar for quality, digital readiness, and compliance is rising fast due to consumer and institutional demands. This shift is continuously helping the migration from unorganized to organized providers. This transformation also presents a generational opportunity for India's In-Vitro Diagnostics Industry. As the nation expands its screening coverage, demand for robust, affordable, and scalable diagnostic solutions is increasing at a fast pace. The next decade offers a defining opportunity to align India's economic strength with its Healthcare ambitions. The time to act is now to invest, innovate, and integrate diagnostics as the gateway to India's universal healthcare dream. We remain deeply committed to our mission of delivering trusted diagnostics with care and precision.
At Dr. Lal PathLabs, with our reference labs backbone, franchisee-led growth model, and investments in high-end diagnostic testing, we are well-positioned to address emerging healthcare challenges. Together, these elements will enable us to grow responsibly while strengthening our leadership in the country. With that, let me invite our CEO, Mr. Shankha Banerjee, to share performance highlights from the quarter. Thank you. Over to you, Shankha.
Thank you, Dr. Lal. Good evening to everyone. It's a pleasure to connect with all of you again as we review the financial performance for the second quarter of fiscal year 2026. In Q2 FY 2026, we have maintained a healthy growth trajectory and strong profitability, reflected in the operational discipline across our network. Revenue growth in Q2 stood at 10.7% year-on-year, with H1 revenue growth at 11%. The Q2 revenue performance was supported by sample volume growth of 10.3% to 25.4 million and patient volume increase of 5% to 8.2 million. In Q2, we recorded a PAT growth of 16.4%. While our core growth was strong, the overall volumes appear moderated on a year-on-year basis, mainly due to lower incidence of seasonal illnesses such as chikungunya, malaria, dengue, and general fever compared to what was observed in the same period last year.
Our focus on deepening our technical expertise in high-complexity testing areas is continuing. Our DNA evolved division incorporates integrated cutting-edge sequencing technology, significantly enhancing our capacity and accuracy for specialized services like personalized medicine and molecular diagnostics across our network. Furthermore, in underscoring our leadership in new age diagnostics, Dr. Lal PathLabs has become the first lab in India to integrate a deep learning-based AI module for detecting lymph node metastasis, including elusive micro-metastasis in cancer cases. This innovation dramatically enhances the precision and speed of oncology reporting, helping clinicians make quicker, life-saving treatment decisions. Our flagship SwasthFit program contributed 26% to Q2 revenues. As an affordable bundled preventive health checkup package, it is the key to securing B2C market access. Given the immense potential of India's nascent preventive testing market, we are confident in driving a continuous increase in SwasthFit's revenue.
We are actively developing new offerings to embed within the bundled program to sustain this trend. Our network expansion is disciplined, driven by a cluster-based approach. We are reinforcing the depth and breadth of our leadership in the core markets of North and East , including Delhi NCR, and are seeing higher revenue contributions from these 10-man clusters. Parallelly, we are intensifying efforts to deepen our reach into Tier 3 and 4 towns to secure future scalability. Our investment in digital assets and technology platforms is helping us improve patient and client experience. We are also increasing applications for AI in our operations, including in-house developed algorithms. Moving forward, growth will be underpinned by geographic expansion, portfolio innovation, and digital enablement. Operationally, our focus is to maximize utilization of the expanded network, drive efficiency, and convert our infrastructure investments into significant operating leverage.
This disciplined approach ensures our continued leadership in the diagnostic sector, delivering sustainable and profitable growth for our shareholders over the long term. With that, I will now hand over the call to our Group CFO and CEO, International Business, Ved . Over to you.
Thank you, Shankha. Good evening, everyone, and a warm welcome. I will be sharing the key financial highlights for Q2 and first half of FY 2026. Revenue for Q2 FY 2026 came in at INR 731 crore compared to INR 660 crore in the same quarter last year, reflecting a growth of 10.7%. The first half FY 2026 revenue stood at INR 1,400 crore, making a growth of 11%. Revenue per patient for Q2 FY 2026 came in at INR 889, 5.4% higher compared to INR 844 in Q2 FY 2025. Test per patient for Q2 FY 2026 stood at 3.09 vs 2.94 in Q2 last year, registering a growth of 5%. EBITDA for Q2 FY 2026 came in at INR 224 crore compared to INR 202 crore in Q2 FY 2025, registering a growth of 10.8% with an EBITDA margin of 30.7%.
EBITDA for first half of FY 2026 stood at INR 416 crore vs INR 370 crore in H1 FY 2025, registering a growth of 11.8% with an EBITDA margin of 29.7%. PBT for Q2 FY 2026 came in at INR 204 crore, registering a growth of 11.2% with a PBT margin of 27.9%. PBT for first half of FY 2026 stood at INR 385 crore with a PBT margin at 27.5%. PAT for Q2 FY 2026 came in at INR 152 crore compared to INR 131 crore in the same quarter last year, registering a growth of 16.4% with a PAT margin of 20.8%. PAT for the first half of FY 2026 stood at INR 286 crore vs INR 239 crore in H1 FY 2025, registering a growth of 20% with a margin of 20.4%. Earnings per share for Q2 FY 2026 was at INR 18.1 compared to INR 15.5 in Q2 FY 2025.
First half FY 2026 EPS stood at INR 33.9 as compared to INR 28.3 in H1 FY 2025. Net cash as of September 30, 2025, stood at INR 1,367 crore. In recognition of this performance and reward to our shareholders, I am happy to share that the Board of Directors has approved an interim dividend of 70%, that is INR 7 per share, and a bonus issue of shares in the ratio of 1:1, that is one bonus equity share for every fully paid equity share held on the record date. With this, I conclude my opening remarks, and I would now request the moderator to open the forum for Q&A.
Thank you very much, sir. We will now begin the question and answer session. Anyone who wishes to ask a question may press star and one on their touchstone telephone. If you wish to withdraw yourself from the question queue, you may press star and two. Participants are requested to use handset while asking a question. Ladies and gentlemen, we'll wait for a moment while the question queue assembles. First question is from the line of Binay from Morgan Stanley. Please go ahead.
Hi team, thanks for the opportunity. My first question is on the revenue growth. When I look at FY 2025, our network expanded by almost 9%. In that, I'm adding the labs, pickup point, and the service centre. If you look at the first half, revenue growth is around 10% or so. Linked to that, how do you rate this revenue performance? You know, because we're also seeing asset turnover, which you shared on slide 10, coming down. How is this revenue trajectory vs your expectation, and what do you think is needed to go into at least a mid-teens or so revenue growth at the company level?
At the beginning of the year, guided revenue growth ranged between 11%- 12% for this financial year, and we are staying with that number even as of now. I think there are two other related points that you make. I think one must understand that new network that one creates isn't going to be at a productivity level of existing network starting from day one or even in year one. It takes some time for networks to mature, and it's an ongoing process. Trying to correlate the number of new network points directly to a percentage revenue growth may not be an appropriate conversion ratio to look at. Also, most of the network that we are talking about is a franchise-led network growth, so that doesn't really need a lot of our own asset creation.
I think the number on the asset turnover, et cetera, is slightly different, which maybe Ved can allude to or try and answer for you. I think the point on percentage number of new network points to revenue growth, there is not a direct one-to-one correlation on that. Ved, you want to talk about the asset turnover?
This asset turnover is compared to, you know, maybe previous one because we have invested in some, you know, property for our expansion. That has also impacted in this asset turnover this time.
Okay, so that has come in the H1 only?
Yes.
Secondly, earlier, you know, we talked about margin compression this year of around 100 basis points. In the last conference call, you said that actually impact could be lower than what you earlier anticipated. How do you see that in the remaining quarters? This again is a pretty good quarter on the margin side, so we've not seen any pressure.
Typically, the margin impact starts reflecting mostly in the second half of the year because the investments that are happening, the costs of that start building up in the second half. That is yet to pan out for us. One thing is that we are definitely maybe looking at a lower impact than maybe what we envisaged at the beginning of the year. I think we think that our margins for the year are likely to be in the range of 27%- 28%.
Okay, the investments will continue, but you're managing it well through cost-cutting initiatives also, which is why the impact is lower than anticipated.
Maybe, Binay, not the cost-cutting, but yeah, some of these efficiency programs, some of these, you know, mix. As SwasthFit also is growing faster, and some of these things are helping us to maintain our margin.
Great, great. Thanks, team. Thanks. I'll come back in the queue.
Thank you.
Thank you.
Thank you. Next question is from the line of Karthik Chellappa from Indus Capital Advisors Hong Kong Limited. Please proceed.
Thank you very much for the opportunity, sir. Just two questions from my side. If we were to correlate the revenue growth along with the volume growth, and if we were to look at our realisation per test, in the last six quarters or so, that has remained more or less in the region of about 1% or below. I'm just curious to understand why is mix not having a bigger impact on our realisation per test? What do you think needs to happen for us to see some sort of acceleration in this metric? Clearly we have resisted taking price hikes. Whatever growth here has to probably come from mix. I'm just curious to understand what will it take for us to see a better outcome on this metric? That's my first question, sir.
Karthik, you know, realisation per test is not a metric we are actively tracking or even trying to bump up. For us, the more relevant metric that we look at more closely is the realisation per patient. The reason is that the cost to serve, et cetera, is more driven by the number of patients that we'll be handling in our own network, as well as the franchisee network. Their cost structure also is about handling more patients. You see, realisation per test metric that you are looking at is not something that we are even actively trying to manage or trying to push up. The mix improvement that you see is a resultant of, which is at the patient level, the realisation per patient is a resultant of higher test per patient, geography mix, and some test mix improvements. All those are bundled in the realisation per patient.
Got it, got it. My second question, sir, is if I were to look at our employee cost growth this quarter, that's only been about 6%- 7%-ish, whereas in the last few quarters, it used to be in the double-digit range. Just curious as to how should we read this? Is it a case where you have already upfronted a lot of your hiring and investments? From here on, there is some operating leverage possible? Or is it just something which is transient, like the timing of festive bonus or so?
I think that number, we'll have to do a slightly more deep dive to maybe come back to you at that level. One, I can tell you that from an employee cost structure or the, you know, increments and things like that, there is nothing out of the ordinary in this quarter versus maybe what we have done. There could be some accounting or the things around it, which we'll have to just check and maybe come back on why is it looking very different than maybe the previous quarter. Maybe Ved can add.
No, Karthik, there is no exception here. I mean, personnel cost is, which is normal. I mean, 7%, 8% growth, which is more driven by the increments and all. There is no exceptional addition which is happening in this quarter, and that's why you might not be, you know, looking. Having said that, the personnel cost is normal, which is, you know, some bit of increment, which we always give, maybe 7%, 8%, and then some addition, which generally we do in the second half of the year.
Got it. One data point, sir, can I get the contribution of West for the quarter into revenue?
We give this once in a year. Generally, we give the contribution, geographical contribution, once in a year.
Okay, perfect. Okay, that's all from my side. Thank you very much, and wish you all the very best for the rest of the year, sir. Thank you.
Thank you.
Thank you. Before we move to the next question, a reminder to the participants to ask a question. You may press star and one. Next question is from the line of Prakash Kapadia from Kapadia Financial Services. Please proceed.
Yeah. Thanks for the opportunity. A couple of questions from my end. In your opening remarks, you mentioned, you know, incidence of dengue and malaria was slightly lower despite, you know, monsoons being good. Was that felt in the northern region or, you know, Pan-India for us, the lower incidence of diseases?
That lower incidence was seen across the country. You know, all the markets that we are operating in, we have seen that impact.
Okay. Shankha, how critical is new product development or specialized products to drive higher revenue growth? Over the last few years, we've been talking about Tier 2, Tier 3 expansion. We've been talking about using our network. We're investing in technology, customer experiences, app differentiation. How critical is new product development or specialized products? Is there a piece of revenue which we target from year on every year, as a percentage, this should contribute to higher growth? You seem to be doing all the right things, but still, we're in that channel of growth. Obviously, you've guided for this kind of growth only, but as investors, they'll mangué more. How critical is this piece to achieve higher growth? There have been obviously some news on technology, cancer-led this thing. How is this portfolio going to differentiate us from others? If you could highlight that, that would really be helpful.
Taking one element and trying to kind of correlate it directly to a growth number for the overall company might be very difficult to connect. However, as an overall portfolio and as our business model, I think new tests are quite important and critical to our success. Dr. Lal PathLabs as a brand is kind of known for being on the leading edge of diagnostic technology, and that is something that we are proud of and we would like to maintain. When there are high-complexity cases which come up or difficult cases that come up with clinicians, we believe that their choice of diagnostic partner will become Dr. Lal PathLabs. When that change happens, then automatically a lot of other kind of portfolio of tests can come to us. It's a kind of a portfolio approach.
From a company perspective and the business model and the profile that we have, launching new tests or having the newest technology, cutting-edge technology on diagnostics, we feel is quite important. Coming back to your question, is there a specific target we set? There are certain divisions that we earmark, and yes, there are certain specific targets for divisions which the sales team looks at. They may not be one-to-one again correlated with the tests that we are talking about right now, because the new tests, when they launch, it also takes time to get disseminated, accepted, and then start using in the clinician network for the benefits that we offer.
Okay. R&D investments could increase because, you know, I think last year we spent on R&D was around INR 4 crore. Is this an area which will increase and will build a differentiated product and leverage on all the things which we have done to also have a complex or a differentiated portfolio?
It will come from different sources. There will be, like you said, R&D, which could be what we do in-house. There could be partnerships, and there can also be tie-ups with other companies or players who are helping, doing some research and then bringing it to life through companies like Dr. Lal PathLabs.
Okay, okay. Understood. Lastly, if you could comment on the Suburban integration, is it over? Is growth coming back? Has growth been in line with what the company average is? Are things stable now?
The Suburban IT integration is completely done. The good news is that now both the brands, Suburban and Dr. Lal PathLabs, in that geography are seamlessly moving between the systems. I think that has started. In terms of the overall growth, I think it's taken slightly longer than what we had envisaged. Right now, I think the way I'm looking at it is maybe by or around Q4 is when we should be able to come back to our original double-digit growth that we were seeing in Suburban before we went for this whole IT changeover.
Got it, got it. Thank you. All the best.
Thank you.
Thank you. Next question is from the line of Anshul Agrawal from Emkay Global. Please go ahead.
Hi, thank you for the opportunity. First question is on revenue trajectory, revenue growth. Despite a muted season and, if I may call it, an unfavorable base, we've continued to grow by growing double digits. Would you want to throw some light around how we have been able to achieve it? Is it like a particular region that has grown outpaced, or has the growth been broad-based, or any strategy that we followed which could help us sort of sustain this momentum despite an unfavorable base?
The growth is quite broad-based for us. I had spoken about it a few quarters back. As we start ramping up our overall testing infrastructure and also the new labs that we are adding, it will kind of start reflecting over a period of time in terms of the organic growth that we should be able to deliver. I think some of those things have started to maybe flow through, and more should come. I think that's one factor. Second is, we have put a lot of renewed focus on Delhi NCR as a region. That has responded, and we have been successfully recording double-digit growth in Delhi NCR as well.
Sure. Any plans to take price hikes this year? I'm assuming it's been almost, it will be almost two years by the end of this calendar year that you've taken any price hike. Any plans to take any price hikes in the current year?
A bit of a correction. By February of 2026, it will be three years since our last price increase. We will look at, evaluate price increasing opportunities maybe around that time. As of now, there isn't something which is immediately on the cards. Getting the organic growth and all the required elements right is the topmost priority. I think once we are confident that the organic growth, the revenue, and the sample volume and the patient volume that we want to see are moving in the right trajectory, I think price increase, adding a layer of price increase on top of that, will be something which we will be able to execute.
Just to add, Anshul, I don't think in this year this price increase is on the card because, you know, another development on account of GST, where people like us are getting some benefit from the reduction of GST rate on our reagents and chemicals. Obviously, that has to be passed on to the customers. This is the other way around, at least, which I can think of. We have to pass on this benefit to the customer, and we are in the process of evaluating how much and at what stage we have to do this. Definitely, price increase in this year is unlikely.
Got it. Just one more question, one last question from my end. We seem to be heavily investing in genomics, the NGS, next-gen sequencing, specialty space. Any color on the market size or our go-to-market strategy that we plan on doing in this segment?
The genomics and sequencing technology, the reason we are investing is not really driven by the market size of today. The way we envisage, I think going forward, this market is going to develop quite fast in the future, and we need to be rightly positioned when, you know, this market becomes much bigger than what it is today. As of now, you know, it's not so much about the revenue numbers, but, you know, getting the right technology, the platforms, you know, the test menu, the TAT around it, the pricing, the cost, and the pricing right, and, you know, our ability to really disseminate all of this to the clinician network, which kind of positions us as and when the need kind of starts growing significantly in this area.
Thank you. That's it from my end.
Thank you.
Thank you. Next question is from the line of Bino Pathiparampil from Elara Capital. Please go ahead.
Hi. Good afternoon, all of you. Congratulations on a great set of quarters. A couple of questions from my side. We have seen the new rates being published by CGHS and possibly other government agencies will follow. Is there any way in which the standalone diagnostic industry benefits from that and our company in particular?
The new CGHS rates which have been announced, I think, are effective around the end of September. It definitely has a beneficial impact on Dr. Lal PathLabs. We have CGHS business as a part of our portfolio. We are still evaluating the level of that impact or the quantum of that impact because some of it would flow maybe quickly, but some of it may come after a lag. We will definitely see some positive impact, but the quantum of that is something which we are still trying to work out.
May I know what percentage of your top line would be benefiting from this, assuming other government agencies also follow?
Like I said, you know, we have business which is CGHS. There is another linked business which is ECHS, which has the defense services kind of comes through it. There are public sector units which follow CGHS price. There are many such things inside. The overall contribution of this portfolio will be maybe 5% or maybe lower than 5% to our overall revenue. Wait, anything else?
Yes, I mean maybe less than 5%, yes.
Got it. Understood. You just alluded to the benefit from GST in the answer to a previous question. Would you be able to quantify a little bit in terms of what sort of margin benefits you expect, and how much of that you would retain?
No. We are not willing to retain anything. I mean, whatever benefit will come, we are willing to pass on to the customer. As far as quantum is concerned, we are in the process to evaluate because there is a process going on. Whatever we will get from our suppliers, the benefit in terms of that will go to customers. It is unlikely that on account of GST, our margins will go up.
Yeah. I think just to add to that, we have no intention of using any benefits through GST to flow through margins. It will get passed on to customers, clients, etc. I think the quantum and the modality of how that will happen is something which is still under review because it's quite a complex calculation given the number of types of reagents and consumables and, you know, the mix of that in our whole test menu. It's a very complex calculation, so it's taking some time for us to really figure out and who's passing how much, etc. We don't have any intention of using any GST benefits passed on for improving margins. We'll rather pass it on to the customers.
Understood. Just a bookkeeping question. The depreciation amount for the quarter is a little higher than previous few quarters. Anything new that has come into that?
I don't think anything new. The only thing we are now, after Suburban Liquidation and, you know, getting into this parent company, there is additional depreciation on intangibles which is coming, but nothing else.
Understood. Thank you very much.
Thank you.
Thank you. Next question is from the line of Chiragh from Keynote Capital. Please go ahead.
Yes. Thank you for the opportunity. Most of my questions are answered. I just have two questions. One is, will it be possible for you to give the H1 mix of specialized portfolio in terms of revenue?
This is not really the number we are sharing at a quarter or a half-year level. I think one thing also one must keep in mind is that there is no standard definition of specialized business across the industry. I think each company has its own way of defining what is specialized and what is not. We have a specialized portfolio. I think that growth and contribution, etc., we will share at the end of the year.
Okay. No issues. My second question is, will it be possible for you to share PO3 plus revenue mix? It was not provided for FY 2025 also. If that is possible for FY 2025 and H1 FY 2026.
Again, Chiragh, some of these data points we are generally giving end of the year because there are certain, you know, ways of calculating, certain ways of, you know, where there are some complexity. As Shankha mentioned, like specialized, each company has their own definition and so on and so forth. Maybe end of this year, we'll provide both these data points.
Okay. Thank you.
Thank you.
Thank you.
Thank you. Next question is from the line of Rishi Modi, who is an individual investor. Please go ahead.
Hello. Shankha, can you hear me?
Yes, please.
Yeah. Shankha, if I, what my research tells me is you all are running an advanced radiology pilot program in Delhi in a few centers. How is that shaping up? How are you looking at it? Are you all there where you all can scale this up, at least in Delhi? How is that panning out?
Currently, we are running high-end radiology, which is CT, MRI-related. Tests that we have started in one center in Delhi and Sihar. What we are seeing is that the scale-up is more or less happening as per our plan, and it is looking robust, fitting in with some of the business practices the way we run it. We have decided to expand that pilot into a few more centers. As and when we are, we would also want to test that the same trajectories and the assumptions hold not only for one center, but at least a few more before we really go for a full-scale scale-up kind of scenario. Those investments are also likely to happen in this financial year, the other few pilots.
Okay. Let's say we understand from the other listed integrated players, it takes about INR 25-30 crore to put up one of these larger centers which have MRI, CT, everything else. Based on your study, how big is the opportunity, say, even if you just start with Delhi within the next couple of years?
We haven't yet done a full opportunity business plan scoping. I think right now we are still at the pilot stage. For us, since this is an addition to existing infrastructure, the investment to start high-end radiology isn't in the range of INR 20-25 crore, like you mentioned. It is lower than that. I think once we are done with all our assessments of our pilots and when we have created our whole scale-up business plan, we'll be able to share that granular detail at that point of time.
Okay. Got it. Second, I wanted to understand, you know, we've been mentioning in our presentations, annual reports, that we're actively looking at South India for an inorganic opportunity. Has there been any progress? Is there any opportunity that one can expect to come through, or anything which you can disclose without, you know, violating any non-public information?
Right now there is nothing which we can share with you. Having said that, this activity is ongoing. As stated earlier, we are always, you know, scouting and keen to expand our South India presence, especially through M&A. Right now, there is nothing which I can share with you.
Got it. Finally, Shankha, you mentioned you all are using an in-house AI for, you know, improving your own processes, systems. Just wanted to understand if you could dwell a bit deeper on what sort of initiatives, apart from that one cancer detection that you mentioned on the operation side, if you could tell me what sort of AI algorithms or AI tech you're using to improve processes? What sort of talent have you hired for this?
Okay. I may not be able to tell you very specifically on what in-house AI we have rolled out. Let me first give you a kind of an overview. For us, there is obviously the medical tech side, which I spoke about in terms of new tests. There is AI which is there in terms of the patient and the testing side of it. There is also a lot of operations that we run where AI algorithms are and can be deployed. That is where some in-house AI algorithms have been created. The talent is, because of this operational thing, primarily in-house. We have developed the algorithm, and maybe some more in the pipeline. Most of that is in-house work.
If I were to understand, the objective is to reduce the costs of current operations, or it's to enable scale for further operations?
It would depend upon the particular use case. Both kinds of use cases are there. There is about enabling scale, improving efficiency, and also about enhancing quality with certain algorithms that help improving in any of these three areas.
Okay. All right. Got it. This is exciting to hear. Thank you for answering my questions, Shankha and Ved Prakash Goel.
Thank you.
Thank you. Next question is from the line of Ashita Jain from Noama. Please go ahead.
Hi. Good day, everyone. I just have two questions. Firstly, on the radiology side, given that you highlighted your planning for a couple of pilot centers, what's an initial outlay that we have thought for our pilot radiology program, if you can highlight that? Also, the capex figure for this year.
Aashita, I mean, it's in the range of flexibles INR 12-1 5 crore kind of outlay for any center, including MRI and CT. CapEx in this year, normal maintenance CapEx is about INR 50, 60 crore. We have bought one property in this year, which is another. Overall, about INR 130, 140 crore kind of CapEx in this year is what we are estimating.
Okay. Thank you. Secondly, just related to this, the property that we have bought in Shalimar Bagh, is this also related to our radiology foray or is it separate? How should we think about it?
It is about enhancing our super specialty testing capabilities. There would be newer departments, higher-end equipment, and new technologies that we will be bringing. It is about enhancing our super specialty capability centrally. I think that's the primary objective. Depending upon size and location right now, it may or may not result in an MRI, CT kind of a thing. That's not really the objective for this location.
Okay. Understood. Any guidelines for the lab or the collection center addition for this year and the next year?
Right now, we can talk about this year. I think beginning of the year itself, I had said 15 to 20 new labs is what we are looking at. We are still guiding the same number. In terms of collection center network, we should be maybe 600 to 800 kind of number of new collection centers this financial year.
Sure. Thank you. This is really helpful. Thank you, and have a good day.
Thank you.
Thank you. Next question is from the line of Yogesh Soni from Incred, please proceed.
Yeah. Thanks for the opportunity. First question is on the Tier 2, 3 cities. If you could let me know how has been the growth in the first half. Secondly, if you could discuss about how the competitive intensity has been in these markets and how are we strategizing our further growth.
I think Ved also mentioned, you see, tier-wise. Growth is a number which we are not giving at a quarterly level. Maybe we look at it and provide that information at an annual level. Coming back to the competitive intensity, you know, competitive intensity, there is a visible competition and there is an invisible competition. We must still, you know, keep in mind that the overall market structure is such that the unorganized pathology sector is still the most dominant player, and the competitive intensity in that part of the business remains quite high. One can't say that intensity has come down at an overall level. Yes, visible competition definitely has been more rational in the recent past than, you know, some time back.
If one wants to understand whether the presence of online players or other hospital diagnostic players has improved in these markets, how should one? I mean, can you help us understand on this?
I think the hospital players are also expanding the retail network. I think that's something which has been visible for the last few quarters, and I think that continues. As the online players, I think they are obviously trying to do their bit in terms of their revenue as well as profitability, which they are doing. I think none of them, none of those have really changed in terms of any strategy that they would be following. Obviously, I can only comment on what we see from outside. Like I said, the growth is not a zero-sum game because still the huge market is unorganized. There is space for everybody to, you know, all types of business models to grow in the diagnostic space.
Understood. One last question which I would want to know is on the growth front. For the last couple of years, we have been doing heavy lab additions and adding the collection centers as well. Our growth has now reached from 10% to around 11%, 12% or so. When can we expect growth to reach early teens or maybe mid-teens over the next two, three years or three to five years of time?
Yeah. I think the basic idea is exactly the way you have outlined it. You see, once we are secured kind of a steady underlying organic growth of, let's say, you know, 11, 12%, I think building a few things on top of that, whether it is, you know, once in three years, once in four years, price increase CAGR, which is lower than inflation, as well as, you know, some one-off kickers which can come through M&As, you know, the long-term CAGR, moving it to a 13, 14% level, definitely will be in a realistic framework for us.
Understood. Thank you. That answers my question.
Thank you. Next question is from the line of Krishna Rajke from Equity Wealth Management Private Limited. Please go ahead.
Hi. Thank you for the opportunity. It was mentioned in the presentation as new therapies for diabetes are increasing. The role of diagnostics will intensify. With the weight loss drugs going off patent next year, do you intend to plan test bundles which will cater to GLP-1? How do you see this opportunity?
I think the GLP-1 drugs going off patent is definitely an opportunity very ripe for the pharma industry. I think on the diagnostic front, I would still say that there are many bundles that we are already available in the market, or from our side rather, in the market, which can help monitor the health of the different organs and multiple sets of organs. Would there be a need for any specific testing bundle just for people who are on GLP-1 or can be on GLP-1 kind of drugs? It's something which we haven't really still come to a final conclusion on.
Okay. Secondly, in the industry, Q3 is generally a softer quarter. With monsoon being extended this time, do you see more volumes this quarter, the next quarter?
I assume by more volumes, you are thinking versus last year in terms of a trend line.
Typically, in terms of more patients reaching out to the diagnostics, we had the monsoons are getting extended.
It is not only about monsoons getting extended. There is also a temperature angle related. It is not just that. Monsoons, I think there is a thing about monsoons, and then there is a thing around temperature. There are multiple things which come together for the fever or the seasonal fever, etc., to come into play. Our belief is that this year, those conditions weren't too favorable. It is unlikely that Q3 will see a catch-up because of that.
Okay. My last question was, when I look at revenue per patient, we are slightly lower compared with the years. How would this number ideally go up? Is it volumes that are driving, or is it more of complex tests that would drive this number?
When you say revenue per patient, down compared to what?
Compared to the previous years, yeah.
Oh, I see. I think, you see, the revenue per patient is a derivative of multiple things. It has a geography, it has a channel mix, and a type of test mix. I think inherently each organization or each company can have a slightly different way of looking at these multiple factors. I think the way we look at it, we are quite happy with the progress we are making on revenue per patient. It is currently growing at about 5% over, you know, same period last year. I think that's quite healthy. We don't envisage this to kind of step up to, you know, organically step up to much higher levels anytime in the near future.
Okay. That's it from my side. Thank you.
Thank you.
Thank you. Next question is from the line of Vivek from MK Global. Please go ahead.
Hi sir. Good evening. Just a point that was mentioned in your presentation, right? I just wanted to understand, you know, that in the Indian market, there has been a narrowing penetration in non-Tier 1 cities over the last five to six years, as you can see in the PPT, right? Does that mean, you know, that demand for pathology in such markets could be a headwind in terms of, you know, if you look at our strategy of expanding into non-Tier 1 markets?
Sorry, maybe I didn't get your question. What are you saying has reduced in non-Tier 1?
The penetration of diagnostic services across Tier 2, 3, 4 cities, if you see page 34 of your presentation.
It has reduced?
Oh, sorry. My bad. I actually saw it in the reverse. Okay. Sorry. Sorry. My bad.
Right. Thank you.
Thank you. Next question is from the line of Surya from Phillip Capital, please proceed.
Yes, thanks for the opportunity, sir. My first question is about the.
Sorry to interrupt, Mr. Surya. Your voice is breaking, sir. We are not able to understand.
Is it audible now?
Yes, sir. Please proceed.
Okay. My first question was on the lab utilization front, sir. On an overall basis, what lab utilization would you be currently having? That is one. A clarification about the CapEx: generally, maintenance CapEx of around INR 60 crore that you have mentioned for the year, but the total CapEx could be around INR 130, 140 crore, what you have mentioned. Is that indicating lab addition only or something else?
Surya, this INR 60 crore +, we bought this property. INR 60 crore includes the lab addition on which we are, you know, saying maintenance because generally we are adding 15- 20 labs. Last year also we added 18. This year also we are planning 15- 20 labs. This is including INR 60 and 75-odd crore we have spent on this property addition.
On your lab utilization point, I think the capacity is not a fixed number in labs. We always try and keep some capacity free for building up volume because it can, you know, adding new equipment or, you know, better or larger throughput machines, increasing the timing of a lab. There are multiple ways in which capacity gets enhanced. There is no formula on saying that this is the capacity utilization one is looking at or working at.
Rather, we would always try and keep some capacity available for ensuring that the growth doesn't get impacted.
Sure, sir. Second question was on the margin front. We had in the fourth quarter mentioned about some margin pressure for the full FY 2026. The kind of run rate we are seeing, despite a relatively weaker season in the second quarter, is better than what we have seen in the previous period. Are you still likely to maintain the kind of margin pressure indication for the full year, which could be seen in the second half? How should one think, or would you revise upward, or how to think about it, sir?
As earlier mentioned, this year we are estimating that between 27%- 28% margins we are confident to maintain. Yes, we had mentioned earlier there is some dilution. In the last quarter we mentioned that it might not be that much. Right now we are estimating between 27%- 28% margins.
Okay. Just last one question from my side, sir, about the same point, the previous question. Revenue per patient. I am seeing that you have very smartly, without raising any price, maintaining a more than 5% kind of growth annually on a revenue per patient level. How sustainable that can be? What levers that you have to sustain this over a period of time if we are not taking any price rise?
I think sustaining 11%-1 2% revenue growth without price hikes is what we are talking about. That comes through a mix of patient sample, RPP. You know, it's kind of a mix playing there because there can also be a scenario where we can have a slightly higher patient growth but a lower RPP growth, right? I think the ability for us to maintain 11%- 12% revenue growth, sustain that consistently, is what are the initiatives and the plans that we've been deploying in the last four to five quarters. I think we seem to be on that. track and on that trajectory. The levers are what I have mentioned earlier, that there is a network, a testing network expansion, that there is this whole SwasthFit bundling that is there. There is a geography and a channel mix improvement that we are doing, and the portfolio test mix improvement. I think those are the points which we mentioned earlier as well are helping us achieve this number.
Okay. Yeah, sure. Thank you. Wish you all the best.
Thank you.
Thank you. Next question is from the line of Abdulkader Puranwala from ICICI Securities. Please go ahead. Mr. Puranwala, your line is unmuted. Please go ahead with your question.
Yes, hi. I hope I'm audible.
Yes.
Thank you for the opportunity. Yeah, just one question about the spirit towards radiology business. How should we look at this as an opportunity? I understand it's on a pilot basis, but in terms of acceptability and the kind of opportunity which this would be in your home market, is this something which can be rolled across the entire Delhi NCR market, or do you believe that this would be within certain pockets in the western side or on the northern side of the home market?
I would not term it as a pivot right now. I think it is more about testing and building our assumptions, testing our assumptions, and looking at the metrics and the levers to use to grow the business sustainably. I think once we are clear, obviously, the first benefit case will be in Delhi NCR. I think if our pilots are all successful, then Delhi NCR will be our business case. I think going beyond that would need fine-tuning of elements, which will take its own time for us to really develop and build. It is unlikely to be looked at as a pivot, but definitely, it's a way to handle the emerging patient expectations of being able to get the integrated diagnostics service under one roof.
Got it, sir. Wish you all the best. Thank you.
Thank you.
Thank you. Next question is from the line of Sumit Gupta from Centrum Broking. Please proceed.
Hi. Good evening. Thanks for the opportunity. Just one question. How do you plan to increase the B2C contribution?
Right now, you see, our B2C contribution is almost three-fourths. Hello?
Yes, sir.
Am I audible? Yeah. Our B2C contribution is almost three-fourths of our overall revenue, and we believe that this is a reasonably good contribution number. In the range of, let's say, if we maintain our range of anything between 74%- 75% of B2C contribution, I think that's good. We are not trying to say that increasing this contribution is going to be a key objective for us going forward.
Okay. Okay. Thank you, sir.
Thank you.
Thank you. Ladies and gentlemen, that was the last question for the day. I would now like to hand the conference over to the management for the closing comments.
Thank you all for joining this call today. We appreciate your continuous trust and support. We hope we have been able to answer all your questions. Please reach out to us in case you have any further queries. Thanks once again. Thank you very much.
Thank you, sir. On behalf of Dr. Lal PathLabs, that concludes this conference. Thank you all for joining us, and you may now disconnect your lines.